Teva Respiratory - News Flash - Israel
Teva Respiratory, the U.S.-based respiratory subsidiary of Israeli Teva Pharmaceutical Industries announced that the FDA has approved its quick relief inhaler ProAir HFA with a dose counter, for the treatment or prevention of breathing disorders in patients four years of age and older. The dose counter is designed to help patients suffering drom disorders such as , Chronic Obstructive Pulmonary Disease (COPD) and Exercise-Induced Bronchospasm (EIB), keep track of the number of doses remaining in the canister. The new product will be commercially available later this year. View and Share
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israeli Startups Create Powerful Drone-Detecting Software
September 28, 2023

Model Sees Daylight As Boost For Hospitalized Patients’ Health
September 28, 2023

Solar Panels On A Roll Certified As Safe For Use In US, Europe
September 28, 2023

US Soldiers, Vets To Get Israeli-Made Helmets To Treat Depression
September 27, 2023
Facebook comments